Prostate cancer mortality also decreased by 4.1% annually between 1994 and 2006, a change thought to be due in large part to PSA screening as there were minimal clinical treatment advances during that time period (Jemal, Siegel, Xu, & Ward, 2010). Here, KLK3 is linked to prostate cancer.